Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMMX Immix Biopharma, Inc.

Trading 05-19 11:54:01 EDT

8.63

-0.36

-4.00%

High8.83	Low8.40	Vol541.59K
Open8.82	D1 Closing8.99	Amplitude4.73%
Mkt Cap469.57M	Tradable Cap351.22M	Total Shares54.41M
T/O4.67M	T/O Rate1.33%	Tradable Shares40.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":8.63,"timestamp":1779206039267,"preClose":8.99,"halted":0,"volume":541592,"delay":0,"changeRate":-0.04004449388209115,"floatShares":40697000,"shares":54411427,"eps":-0.888277,"marketStatus":"Trading","change":-0.36,"latestTime":"05-19 11:54:01 EDT","open":8.82,"high":8.825,"low":8.4,"amount":4667481.558584,"amplitude":0.047275,"askPrice":8.66,"askSize":230,"bidPrice":8.62,"bidSize":9,"shortable":3,"etf":0,"ttmEps":-0.888277,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779220800000},"marketStatusCode":2,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":8.99,"preHourTrading":{"tag":"盘前","latestPrice":9.04,"preClose":8.99,"latestTime":"08:09 EDT","volume":55,"amount":494.93999499999995,"timestamp":1779192596924,"change":0.05,"changeRate":0.005562,"amplitude":0.012236},"postHourTrading":{"tag":"盘后","latestPrice":9.05,"preClose":8.99,"latestTime":"19:27 EDT","volume":697,"amount":6349.11,"timestamp":1779146833157,"change":0.06,"changeRate":0.006674,"amplitude":0.040044},"volumeRatio":1.994016,"impliedVol":1.4264,"impliedVolPercentile":0.5657},"requestUrl":"/m/hq/s/IMMX","defaultTab":"news","newsList":[{"id":"2635072776","title":"Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2635072776","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635072776?lang=en_us&edition=fundamental","pubTime":"2026-05-15 11:18","pubTimestamp":1778815119,"startTime":"0","endTime":"0","summary":"Immix Biopharma investor presentation highlighted NXC-201, a BCMA-targeted CAR-T program for relapsed or refractory AL amyloidosis, a setting it estimates at about 38,500 U.S. patients with no FDA-approved therapies.Clinical data referenced from ASH 2025 showed a 75% complete response rate for NXC-201, versus 0%-10% complete response rates cited for investigator’s-choice regimens used off label in this population.Presentation outlined a registrational-design NEXICART-2 U.S. trial, with a planned topline readout in Q3 2026.Commercial planning targets launch in 1H 2027, with buildout focused on high-prescribing treatment sites.Market framing assumed existing reimbursement benchmarks for BCMA CAR-T at about $422,000 per patient, positioning opportunity as multi-billion-dollar scale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4wVG0P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635816157","title":"3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635816157","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635816157?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:05","pubTimestamp":1778670334,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business and potential for substantial earnings expansion.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/5122000-choice1-main-header/1585186630654","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5122000-choice1-main-header/1585186630654"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-ofrm/once-upon-a-farm-pbc/news/3-growth-companies-with-high-insider-ownership-expect-earnin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-ofrm/once-upon-a-farm-pbc/news/3-growth-companies-with-high-insider-ownership-expect-earnin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B19Z9P08.USD","LU0353189680.USD","OFRM","BK4187","BK4505","BK4141","UPSX","BK4585","BK4212","RUM","BK4563","LU1861220033.SGD","IE00B19Z9Z06.USD","LU1861215975.USD","LU2290526834.HKD","BK4214","LU1852331112.SGD","LU2250418816.HKD","BK4613","IE00B894F039.SGD","BK4122","LU2931357623.SGD","BK4561","IE00BZ9MQY76.HKD","LABX","BK4588","LU2360106780.USD","BK4608","APPX","BK4539","IMMX","BK4166","BK4135","BK4023","BK4077","BK4006","LU0056508442.USD","LU0097036916.USD","BK4082","LU2089985449.USD","BK4009","BK4139","BK4516","LU0353189763.USD","LU2087625088.SGD","LU0274383776.USD","LU2360107168.USD","LU2063271972.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635229646","title":"Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2635229646","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635229646?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:21","pubTimestamp":1778628087,"startTime":"0","endTime":"0","summary":"Immix Biopharma investor presentation highlighted NXC-201, a BCMA-targeted CAR-T being developed for relapsed or refractory AL amyloidosis, a setting it estimates at about 38,500 U.S. patients with no FDA-approved drugs.Clinical data referenced from ASH 2025 showed a 75% complete response rate for NXC-201, versus 0-10% complete response cited for current investigator’s-choice regimens in relapsed or refractory disease.Company outlined a registrational design for U.S. NEXICART-2, with final readout targeted for topline in Q3, followed by a planned BLA submission.Commercial timeline calls for launch planning in late 2026, with a commercial launch plan in 1H 2027.Presentation also framed NXC-201 as a platform candidate beyond AL amyloidosis, targeting plasma cells across selected immune-mediated diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL7Yt8JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633310508","title":"Immix Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633310508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633310508?lang=en_us&edition=fundamental","pubTime":"2026-05-08 07:19","pubTimestamp":1778195953,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc reports results for the quarter ended March 31 - Earnings SummaryImmix Biopharma Inc IMMX.OQ reported a quarterly adjusted loss of 18 cents per share for the quarter ended March 31","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K3N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633103993","title":"Immix Biopharma Q1 net loss widens to USD 10.09 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633103993","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633103993?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:20","pubTimestamp":1778192428,"startTime":"0","endTime":"0","summary":"Immix Biopharma posted a net loss of USD 10.09 million for the quarter ended March 31, 2026, widening from USD 4.54 million a year earlier.Research and development expense climbed to USD 5.98 million from USD 1.98 million, while general and administrative costs rose to USD 4.82 million from USD 2.71 million.Interest income increased to USD 717,168 from USD 150,219, reflecting interest on money market funds and US Treasuries.Cash, cash equivalents, and short-term investments totaled about USD 90.6 million at March 31, 2026; total assets were about USD 95.8 million with working capital of about USD 81.7 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL6thqzg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633961673","title":"Immix Biopharma Inc  expected to post a loss of 21 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633961673","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633961673?lang=en_us&edition=fundamental","pubTime":"2026-05-05 05:14","pubTimestamp":1777929261,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc  expected to post a loss of21cents a share - Earnings Preview Immix Biopharma Inc IMMX.OQ IMMX.O is expected to  report resultson May 6 (estimated) for the period ending March 31 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H2EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633950636","title":"Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2633950636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633950636?lang=en_us&edition=fundamental","pubTime":"2026-05-05 02:15","pubTimestamp":1777918512,"startTime":"0","endTime":"0","summary":"Immix Biopharma investor presentation highlighted clinical data for BCMA-targeted CAR-T NXC-201 in relapsed or refractory AL amyloidosis.ASH 2025 dataset cited 75% complete response rate for NXC-201, versus 0-10% complete response rate cited for current investigator’s choice regimens in this setting.U.S. relapsed or refractory AL amyloidosis population estimated at about 38,500 patients, with no FDA-approved therapies cited for this segment.Commercial planning cited launch in 1H 2027, supported by 20 high-prescribing sites in existing clinical trial network.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL3V56kV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632883139","title":"Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2632883139","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632883139?lang=en_us&edition=fundamental","pubTime":"2026-05-03 23:36","pubTimestamp":1777822594,"startTime":"0","endTime":"0","summary":"Immix Biopharma investor presentation highlighted NXC-201, a BCMA-targeted CAR-T program positioned for relapsed or refractory AL amyloidosis, where it estimates about 38,500 patients in US lack an FDA-approved treatment option.Clinical data referenced from ASH 2025 showed a 75% complete response rate for NXC-201 in relapsed or refractory AL amyloidosis, versus 0%-10% complete response rates cited for current investigator’s-choice regimens.Reimbursement benchmark for BCMA CAR-T was cited at about $422,000, framing a multi-billion-dollar commercial opportunity based on the estimated patient pool.Development timeline pointed to NXC-201 NEXICART-2 as a US trial with registrational design, with final readout targeted for a Q3 topline and a commercial launch plan in 1H 2027.Presentation also outlined potential expansion into immune-mediated diseases beyond AL amyloidosis, with neurology and rheumatology among highlighted areas.Disclaimer: This news brief was created by Public Technologies  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260503:nNDL64kkGj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626739182","title":"Immix Biopharma to participate in Jefferies Global Healthcare Conference, hosts investor meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2626739182","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626739182?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:45","pubTimestamp":1775738735,"startTime":"0","endTime":"0","summary":"Immix Biopharma will participate in Jefferies Global Healthcare Conference June 2-4, 2026 in New York.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL3sCP2D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4588","SG9999014021.USD","BK4585","IE00BKPKM429.USD","BK4112","IE00B64PRP62.GBP","IMMX","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014005.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625860127","title":"Immix Biopharma announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625860127","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625860127?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:38","pubTimestamp":1775507928,"startTime":"0","endTime":"0","summary":"Immix Biopharma scheduled annual shareholder meeting in Los Angeles on May 22, 2026.Shareholders will vote to elect nine directors to serve until next annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL846Dx5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623898765","title":"Infinimmune: Under Agreement, Merck Will Have Exclusive Right to Develop and Commercialize Antibody Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623898765","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623898765?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:05","pubTimestamp":1774958720,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J1EC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BBT3K403.USD","LU0965508806.USD","LU0006306889.USD","LU0320765646.SGD","LU1934455194.USD","LU1162221912.USD","LU0861579265.USD","LU0965509101.SGD","LU1291159041.SGD","IE00BJJMRZ35.SGD","LU1934455277.USD","LU0208291251.USD","LU0265550359.USD","LU0130517989.USD","LU2360032135.SGD","LU0985320562.USD","IMMX","LU1989771016.USD","LU1066051811.HKD","MRK","LU2468319806.SGD","LU2461242641.AUD","IE00B2B36J28.USD","LU1974910355.USD","IE00B4R5TH58.HKD","LU0058720904.USD","LU0648001328.SGD","LU0868494708.USD","SG9999001176.SGD","LU0980610538.SGD","LU1983299246.USD","LU1934455863.HKD","LU1989772923.USD","BK4533","BK4588","LU1116320901.HKD","LU0238689110.USD","SG9999014559.SGD","LU1057294990.SGD","LU2089984988.USD","LU1093756168.USD","LU0965509010.AUD","IE00B1BXHZ80.USD","LU1929549753.HKD","IE00BJT1NW94.SGD","LU0234572021.USD","LU0265550946.USD","SG9999013999.USD","IE0009355771.USD","LU2023250504.SGD","SG9999002232.USD","LU1430594728.SGD","SG9999015341.SGD","LU2125154935.USD","LU1989772840.SGD","SG9999002224.SGD","IE00BLSP4452.SGD","LU1571399168.USD","LU0070302665.USD","LU1116320737.USD","IE00BN8TJ469.HKD","LU1037948897.HKD","LU0266013472.USD","BK4516","LU2125154778.USD","LU1066051225.USD","LU1066053197.SGD","SG9999001176.USD","LU1585245621.USD","LU0477156953.USD","LU2324357040.USD","LU0211331839.USD","LU0203347892.USD","LU0203345920.USD","LU1941712348.USD","LU0965509283.SGD","BK4585","LU1023059063.AUD","LU1035773651.USD","LU2112291526.USD","LU2361044865.SGD","BK4559","BK4007","BK4550","LU0868494617.USD","SG9999014567.USD","LU1917777945.USD","LU0106261372.USD","IE0002141913.USD","LU1201861249.SGD","LU1066051498.USD","LU0320765489.SGD","LU2361045086.USD","BK4534","LU1037948541.HKD","LU1061106388.HKD","SG9999015358.SGD","SG9999014542.SGD","IE00BSNM7G36.USD","LU1093756325.SGD","SG9999014575.USD","LU0130102774.USD","IE00BFTCPJ56.SGD","LU1069347547.HKD","LU1941712264.USD","LU0098860793.USD","LU2106854487.HKD","LU1699723380.USD","LU0289739699.SGD","SGXZ57979304.SGD","LU2361044949.HKD","LU0942090050.USD","SG9999001440.SGD","LU0122379950.USD","LU0432979614.USD","IE00BLSP4239.USD","LU2023250843.SGD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623328908","title":"Immix Biopharma Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2623328908","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623328908?lang=en_us&edition=fundamental","pubTime":"2026-03-31 01:43","pubTimestamp":1774892580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 13:43 ET (17:43 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623459893","title":"Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon","url":"https://stock-news.laohu8.com/highlight/detail?id=2623459893","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623459893?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:38","pubTimestamp":1774877922,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced that NEXICART-2 enrollment is complete, meeting company guidance, with topline results expected in Q3, followed by...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-completes-nexicart-2-enrollment-onboards-cmo-richard-graydon-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-completes-nexicart-2-enrollment-onboards-cmo-richard-graydon-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623310705","title":"Immix Biopharma completes enrollment in NEXICART-2 AL amyloidosis BLA-enabling trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623310705","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623310705?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:45","pubTimestamp":1774874730,"startTime":"0","endTime":"0","summary":"Immix Biopharma completed enrollment in NEXICART-2, its BLA-enabling trial in relapsed or refractory AL amyloidosis.Positive interim data were previously presented at ASH 2025.Topline NEXICART-2 results are expected in Q3 2026.BLA submission is planned following topline results, with commercial launch planned thereafter.Richard Graydon joined as chief medical officer to support BLA submission.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL8f0s4m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","IMMX","LU2210150020.SGD","BK4588","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623310711","title":"Immix Biopharma Announces Enrollment Completion of Bla-Enabling Relapsed/Refractory Al Amyloidosis Trial Nexicart-2, and Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2623310711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623310711?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:45","pubTimestamp":1774874700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA7FGJWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622823988","title":"Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622823988","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622823988?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:08","pubTimestamp":1774609680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 07:08 ET (11:08 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847028","title":"Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $15 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847028?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:11","pubTimestamp":1774606293,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nAZN4SNMI4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845792","title":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622845792?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:54","pubTimestamp":1774598066,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex HoldingsMarch 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4N40F0FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOXA","AGX","BK4561","GOOX","SPXC","BALY","GOOW","ADP","DISO","MASI","KYIV","LU1815333072.USD","GOOP","U","OXY","PRMB","GOU","KOD","BIOA","IE00BMPRXQ63.HKD","BK4134","IMMX","LBRX","CCL","DIS","GNRC","MGTX","OLPX","BTGO","OXM","UNX","GGLL","GOOY","PLU","IT","COP","GOOGL","BK4551","ATAI","CHRD","CMC","GGLS","HAL","NHI","PL","CTAS","LU0345769128.USD","FISV","EOG","PHAT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622860508","title":"Immix Biopharma, Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622860508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622860508?lang=en_us&edition=fundamental","pubTime":"2026-03-26 08:57","pubTimestamp":1774486675,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc reports results for the quarter ended December 31 - Earnings SummaryImmix Biopharma, Inc IMMX.OQ reported a quarterly adjusted loss of 28 cents per share for the quarter ended Dec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E00Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000248","title":"Immix Biopharma Q4 EPS $(0.28) Misses $(0.16) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000248","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000248?lang=en_us&edition=fundamental","pubTime":"2026-03-26 06:13","pubTimestamp":1774476811,"startTime":"0","endTime":"0","summary":"Immix Biopharma (NASDAQ:IMMX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.16) by 75 percent. This is a 75 percent decrease over losses of $(0.16) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51472287/immix-biopharma-q4-eps-0-28-misses-0-16-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Immix Biopharma Q4 EPS $(0.28) Misses $(0.16) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":-0.0937},{"period":"1month","weight":-0.1314},{"period":"3month","weight":0.1071},{"period":"6month","weight":1.1253},{"period":"1year","weight":3.3641},{"period":"ytd","weight":0.7189}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035123},{"month":2,"riseRate":0.2,"avgChangeRate":-0.05746},{"month":3,"riseRate":0.2,"avgChangeRate":-0.065433},{"month":4,"riseRate":0.4,"avgChangeRate":-0.025442},{"month":5,"riseRate":0.6,"avgChangeRate":0.091323},{"month":6,"riseRate":0.5,"avgChangeRate":0.09241},{"month":7,"riseRate":0.5,"avgChangeRate":0.015932},{"month":8,"riseRate":0.25,"avgChangeRate":-0.104667},{"month":9,"riseRate":0.25,"avgChangeRate":0.017421},{"month":10,"riseRate":0.75,"avgChangeRate":0.171445},{"month":11,"riseRate":1,"avgChangeRate":0.264693},{"month":12,"riseRate":1,"avgChangeRate":0.380003}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc.","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immix Biopharma, Inc.,IMMX,Immix Biopharma, Inc.股票,Immix Biopharma, Inc.股票老虎,Immix Biopharma, Inc.股票老虎国际,Immix Biopharma, Inc.行情,Immix Biopharma, Inc.股票行情,Immix Biopharma, Inc.股价,Immix Biopharma, Inc.股市,Immix Biopharma, Inc.股票价格,Immix Biopharma, Inc.股票交易,Immix Biopharma, Inc.股票购买,Immix Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction